Michael Burgess's most recent trade in Synlogic Inc was a trade of 30,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 22, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Synlogic Inc | Michael Burgess | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| SpringWorks Therapeutics Inc | Michael Burgess | Head of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.47 per share. | 18 Jul 2022 | 3,103 | 49,584 (0%) | 0% | 28.5 | 88,342 | Common Stock |
| Synlogic Inc | Michael Burgess | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 27,000 | 27,000 | - | - | Stock Option (right to buy) | |
| SpringWorks Therapeutics Inc | Michael Burgess | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 12,185 | 52,687 (0%) | 0% | 0 | Common Stock | |
| SpringWorks Therapeutics Inc | Michael Burgess | Head of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.61 per share. | 01 Jun 2022 | 2,672 | 40,502 (0%) | 0% | 19.6 | 52,398 | Common Stock |
| SpringWorks Therapeutics Inc | Michael Burgess | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 48,852 | 48,852 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Michael Burgess | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 15,674 | 43,174 (0%) | 0% | - | Common Stock |